Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI

SILVER extension study (n=107) found that continuous glucose monitoring over 1 year decreased HbA1c (-0.35% vs previous self-monitoring of blood glucose during GOLD RCT; 95% CI -0.19 to -0.50%; P < 0.001) and reduced time in hypoglycaemia with increased treatment satisfaction.

Diabetes Care